Anti-TNF therapy for Crohn's disease: A perspective (infliximab is not the drug we have been waiting for)

Inflammatory Bowel Diseases

Volumn 6, Issue 2, 2000, Pages 137-139

  Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; DRUG ANTAGONISM; HUMAN; NOTE; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034186168     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200005000-00011     Document Type: Article

References (5)

1. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflammatory Bowel Diseases 1999;5: 119-33.
2. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997;337:1029-35.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405.
4. Shanahan F, O Sullivan GC, Collins JK. Genes, bacteria, and T cells: ingredients for inflammatory bowel disease. Gastroenlerology 1998:115:1595-1600.
5. Feagan B. Antibiotics are not effective therapy for Crohn's disease (time to remove the rose-coloured glasses). Inflammatory Bowel Diseases 1997;3:314-17.